X1 Biotech
X1 Biotech is advancing X101, a repurposed small-molecule RUNX1 inhibitor, through a capital-efficient rare-disease strategy to enable broader impact.
Total raised
$235K
3 rounds on record
Last round
$40K
Jun 2026
Why it's on the radar
TeamFundraising signals (who's likely raising, and why) are on Team.Start a free 14-day trial →Funding history · 3 rounds
Jun 2026Form D$40KSEC filing
May 2025Form D$95KSEC filing
May 2025Form D$100KSEC filing
Key people
ProKey people, exec moves and open roles are on Pro.Start a free 14-day trial →